Clinical and pathological implications of the presence of MECA-79-expressing tumor cells in pathological stage IA lung adenocarcinoma.

ABSTRACT: Approximately 15% of patients with resected pathological stage IA lung adenocarcinoma develop recurrent disease, indicating the formation of a cancer metastasis-promoting microenvironment, and highlighting the importance of identifying early prognostic biomarkers. The MECA-79 epitope is a glycan structure modulating immune response, normally expressed on high endothelial venules. Ectopic MECA-79 expression has been recently reported in several cancer cells and is associated with poor prognosis. In this retrospective cohort study, we aimed to investigate the clinical and pathological significance of tumoral MECA-79 expression in early-stage lung cancer. Immunohistochemical analysis for MECA-79 was performed in 195 patients with pathological stage IA lung adenocarcinoma undergoing lobectomy.

SUBMITTER: Saito T 

PROVIDER: S-EPMC12530585 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature